Item-Level Scores on the Boston Naming Test as an Independent Predictor of Perirhinal Volume in Individuals with Mild Cognitive Impairment

Author:

De Marco Matteo1,Bocchetta Martina12ORCID,Venneri Annalena13,

Affiliation:

1. Centre for Cognitive and Clinical Neuroscience, Division of Psychology, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London UB8 3PH, UK

2. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London WC1E 6BT, UK

3. Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy

Abstract

We explored the methodological value of an item-level scoring procedure applied to the Boston Naming Test (BNT), and the extent to which this scoring approach predicts grey matter (GM) variability in regions that sustain semantic memory. Twenty-seven BNT items administered as part of the Alzheimer’s Disease Neuroimaging Initiative were scored according to their “sensorimotor interaction” (SMI) value. Quantitative scores (i.e., the count of correctly named items) and qualitative scores (i.e., the average of SMI scores for correctly named items) were used as independent predictors of neuroanatomical GM maps in two sub-cohorts of 197 healthy adults and 350 mild cognitive impairment (MCI) participants. Quantitative scores predicted clusters of temporal and mediotemporal GM in both sub-cohorts. After accounting for quantitative scores, the qualitative scores predicted mediotemporal GM clusters in the MCI sub-cohort; clusters extended to the anterior parahippocampal gyrus and encompassed the perirhinal cortex. This was confirmed by a significant yet modest association between qualitative scores and region-of-interest-informed perirhinal volumes extracted post hoc. Item-level scoring of BNT performance provides complementary information to standard quantitative scores. The concurrent use of quantitative and qualitative scores may help profile lexical–semantic access more precisely, and might help detect changes in semantic memory that are typical of early-stage Alzheimer’s disease.

Funder

Alzheimer’s Association Research

Alzheimer’s Society, UK

European Union

National Institutes of Health

Department of Defense

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie, Alzheimer’s Association

Alzheimer’s Drug Discovery Foundation

Araclon Biotech

BioClinica, Inc.

Biogen

Bristol Myers Squibb Company

CereSpir, Inc.

Cogstate

Eisai Inc.

Elan Pharmaceuticals, Inc.

Eli Lilly and Company

EuroImmun

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Fujirebio

GE Healthcare

IXICO Ltd.

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson & Johnson Pharmaceutical Research & Development LLC.

Lumosity

Lundbeck

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

NeuroRx Research

Neurotrack Technologies

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Piramal Imaging

Servier

Takeda Pharmaceutical Company

Transition Therapeutics

Canadian Institutes of Health Research

Foundation for the National Institutes of Health

Publisher

MDPI AG

Subject

General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3